feed,title,long_url,short_url
Benzinga,InflaRx's Vilobelimab Suppresses Inflammation In Mid-Stage Chronic Skin Disorder Study,https://www.benzinga.com/general/biotech/21/02/19612316/inflarxs-vilobelimab-suppresses-inflammation-in-mid-stage-chronic-skin-disorder-study,https://j.mp/3qi5iYQ
